C4 Therapeutics (CCCC)
(Real Time Quote from BATS)
$4.44 USD
-0.11 (-2.42%)
Updated Jul 5, 2024 03:30 PM ET
3-Hold of 5 3
F Value D Growth C Momentum F VGM
Price, Consensus and EPS Surprise
CCCC 4.44 -0.11(-2.42%)
Will CCCC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CCCC
C4 Therapeutics, Inc. (CCCC) Reports Q4 Loss, Misses Revenue Estimates
Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics (CCCC) to Report Q4 Earnings: What's in Store?
C4 Therapeutics, Inc. (CCCC) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
Inhibrx, Inc. (INBX) Soars 8.9%: Is Further Upside Left in the Stock?
Other News for CCCC
C4 Therapeutics: Losing Steam And Presenting An Opportunity
C4 Therapeutics Appoints Mr. Cooper to Board
C4 Therapeutics Appoints Ron Cooper as Chairman of the Board of Directors
C4 Therapeutics appoints Cooper as Chairman of Board of Directors
CCCC Makes Notable Cross Below Critical Moving Average